Aligos Therapeutics Announced Friday A Research Collaboration And Development Agreement With Xiamen Amoytop Biotech Co. Ltd. For Use Of Aligos' Oligonucleotide Platform For Treatment Of Liver Diseases
Aligos Therapeutics Announced Friday A Research Collaboration And Development Agreement With Xiamen Amoytop Biotech Co. Ltd. For Use Of Aligos' Oligonucleotide Platform For Treatment Of Liver Diseases
Aligos Therapeutics, Inc. (NASDAQ:ALGS, " Aligos" , the " Company" ))))), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced that it has entered into a research collaboration and development agreement with Xiamen Amoytop Biotech Co. Ltd. ("Amoytop") for the use of Aligos' oligonucleotide platform to discover, research and develop oligonucleotides for the treatment of liver diseases in the Greater China territory.
Aligos Therapeutics, Inc.（納斯達克股票代碼：ALGS，“Aligos”，“公司”））是一家臨床階段的生物製藥公司，專注於開發用於解決肝臟和病毒性疾病未得到滿足的醫療需求的新療法。該公司今天宣佈，它已與廈門Amoytop Biotech有限公司簽訂了研究合作和開發協議。Ltd.（“Amoytop”）利用Aligos的寡核苷酸平臺在大中華地區發現、研究和開發用於治療肝臟疾病的寡核苷酸。
Under the terms of the agreement, Aligos and Amoytop will collaborate on the research and development of oligonucleotide compounds for the treatment of liver diseases. Amoytop will receive an option to obtain an exclusive license to develop and commercialize the resultant products in the Greater China territory while Aligos will retain rest-of-world rights. Aligos will also receive an upfront payment and research collaboration funding and be eligible to receive up to a total of $109 million in development and sales milestone payments for licensed products as well as tiered royalties on net sales.
根據協議條款，Aligos和Amoytop將合作研究和開發用於治療肝臟疾病的寡核苷酸化合物。Amoytop 將獲得獨家許可，在大中華地區開發和商業化由此產生的產品，而 Aligos 將保留世界其他地區的版權。Aligos還將獲得預付款和研究合作資金，並有資格獲得總額高達1.09億美元的許可產品的開發和銷售里程碑補助金，以及淨銷售額的分級特許權使用費。